Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para evaluar la eficacia y seguridad de Belantamab Mafodotin en combinación con Ciclofosfamida, Bortezomib y Dexametasona en participantes adultos con amiloidosis de cadena ligera (AL) recién diagnosticada (ALANIS)

2 de noviembre de 2026 actualizado por: GlaxoSmithKline

Un Estudio de Fase 2, Abierto, de un Solo Brazo, de Prueba de Concepto que Evalúa la Eficacia y Seguridad de Belantamab Mafodotin Administrado en Combinación con Ciclofosfamida, Bortezomib y Dexametasona en Participantes Adultos con Amiloidosis de Cadenas Ligeras Recién Diagnosticada (ALANIS)

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 2

Acceso ampliado

Disponible fuera del ensayo clínico. Ver registro de acceso ampliado.

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • New South Wales
      • Westmead, New South Wales, Australia, 2145
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Fiona Kwok
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Nirija Ranjit Anderson
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Angelina Yong
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Brendan Wisniowski
      • Fitzroy, Victoria, Australia, 3065
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Matthew Rees
      • Frankston, Victoria, Australia, 3199
        • Reclutamiento
        • GSK Investigational Site
        • Investigador principal:
          • Patricia Walker
        • Contacto:
        • Contacto:
    • California
      • Los Angeles, California, Estados Unidos, 90048-1804
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Robert Vescio
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Jorge Monge Urrea
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06511
        • Reclutamiento
        • GSK Investigational Site
        • Investigador principal:
          • Sabrina Browning
        • Contacto:
        • Contacto:
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02118-2307
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Andrew Staron
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Shaji Kumar
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Pooja Phull
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Phyu Naing
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Amandeep Godara
      • Liverpool, Reino Unido, L7 8YA
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Stephen Hawkins
      • London, Reino Unido, NW1 2BU
        • Reclutamiento
        • GSK Investigational Site
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Ashutosh Wechalekar

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

  • Participant is at least 18 years of age or the legal age of consent

  • Has histologically confirmed newly diagnosed primary AL amyloidosis according to the following criteria:

    • Presence of an amyloid-related systemic syndrome as per consensus guidelines.
    • Positive amyloid staining by Congo red stain with green birefringence on polarized light microscopy in any tissue AND at least 1 of the following tests to confirm amyloid type as AL Characteristic appearance by electron microscopy or confirmatory immunohistochemistry or AL amyloidosis typing by mass spectrometric proteomic analysis of the amyloid deposits or amyloid-typing by immunofluorescence oEvidence of a monoclonal plasma cell proliferative disorder
  • Measurable clonal disease as defined by at least 1 of the following:

    • Serum monoclonal protein >=0.5 grams per deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation performed at central laboratory),
    • Involved serum FLC >=5.0 milligram per deciliter (mg/dL) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved light chain, FLC concentrations (dFLC) >=5 mg/dL.
  • Not considered candidate for high-dose chemotherapy with autologous stem cell transplantation (ASCT) as part of first line of therapy

  • Is willing to use adequate contraception.

  • Is capable of giving signed informed consent

  • Has an Eastern Cooperative Oncology Group performance status of 0, 1 or 2

  • Has adequate hematologic, hepatic and renal function

Exclusion criteria:

  • Has a previous or current diagnosis of plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome or symptomatic multiple myeloma (MM), as per International Myeloma Working Group criteria for MM including the presence of lytic bone disease , plasmacytomas, or clonal BM plasma cells >=60%.

  • Has Immunoglobulin M (IgM)-related AL amyloidosis.

  • Has any form of non-AL amyloidosis, including wild type or mutated (Transthyretin amyloidosis [ATTR]) amyloidosis.

  • Has evidence of significant cardiovascular (CV) conditions as specified below:

    • New York Heart Association (NYHA) classification IIIb or IV heart failure.
    • Heart failure that in the opinion of the investigator is caused by ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram [ECG] changes) or uncorrected valvular disease and not primarily due to AL amyloidosis cardiomyopathy.
    • In-participant admission to a hospital for unstable angina or myocardial infarction within the last 3 months prior to screening or percutaneous cardiac intervention with recent stent within last 3 months prior to screening or coronary artery bypass grafting within the last 3 months prior to screening
    • Participants with current evidence of clinically significant untreated arrhythmia(s), including clinically significant ECG abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.
    • Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillator is indicated but not placed (participants who do have a pacemaker/implantable cardioverter-defibrillator are allowed on the study).
    • Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >450 millisecond (msec) or >480 msec for participants with bundle branch block. Participants who have a pacemaker may be included regardless of calculated QTc interval.
    • Supine systolic blood pressure <90 millimeters of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of >20 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion.
    • Uncontrolled hypertension.
  • Has Mayo stage 3B disease

  • Has a current corneal epithelial disease except for mild punctate keratopathy.

  • Has previous or concurrent malignancies other than AL amyloidosis, except for any other malignancy that has been considered medically stable for at least 2 yearsThe participant must not be receiving active therapy, other than hormonal therapy for this disease.

  • Has major surgery within 2 weeks prior to the first dose of study interventions or has not recovered fully from surgery.

  • Has any history of prior allogenic or autologous BM transplant or other solid organ transplant.

  • Has known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, cyclophosphamide, bortezomib, boron or mannitol

  • Has active infection or active bleeding.

  • Has intolerance or contraindications to antiviral prophylaxis.

  • Has known Human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:

    • Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/milliliter (mL) Cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >=350 cells/microliter.
    • No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months.
  • Has prior therapy for AL amyloidosis or MM, with the exception of 160 milligram (mg) dexamethasone (or equivalent corticosteroid) maximum exposure prior to enrollment.

  • Has received any live or live-attenuated vaccine within 30 days prior to first dose of belantamab mafodotin

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research within 28 days before enrollment.

  • Has an alanine aminotransferase (ALT) value >2.5*upper limit of normal (ULN) or >3*ULN if hepatic involvement of AL amyloidosis

  • Has a total bilirubin value >1.5*ULN

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment Has documented presence of Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention, unless HBV DNA is undetectable at screening and participant receives antiviral prophylaxis or treatment.

  • Has a positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the following criteria are met:

    • RNA test negative.
    • Successful antiviral treatment (usually 8 weeks duration), followed by a negative Hepatitis C virus RNA test after a washout period of at least 4 weeks.
  • Chronic hepatitis B infection, with the presence of HBsAg and/or detectable hepatitis B virus deoxyribonucleic acid (HBV DNA), and hepatitis D co-infection, with hepatitis D antibody and/or RNA, within 3 months

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dose optimization phase: Belantamab mafodotin dose level 1 + CyBorD

Adult participants with newly diagnosed amyloid light chain (AL) amyloidosis will receive Belantamab mafodotin dose level 1 in combination with CyBorD in dose optimization phase.

Belantamab mafodotin will be administered

Cyclophosphamide will be administered

Bortezomib will be administered

Dexamethasone will be administered

Experimental: Dose optimization phase: Belantamab mafodotin dose level 2+ CyBorD

Adult participants with newly diagnosed AL amyloidosis will receive Belantamab mafodotin dose level 2 in combination with CyBorD in dose optimization phase.

Belantamab mafodotin will be administered

Cyclophosphamide will be administered

Bortezomib will be administered

Dexamethasone will be administered

Experimental: Dose expansion phase: Belantamab mafodotin + CyBorD

Adult participants with newly diagnosed AL amyloidosis will receive belantamab mafodotin at selected dose level from dose optimization phase in combination with CyBorD in dose expansion phase.

Belantamab mafodotin will be administered

Cyclophosphamide will be administered

Bortezomib will be administered

Dexamethasone will be administered

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall complete hematologic response (CHR) rate
Periodo de tiempo: Up to approximately 24 months

The overall CHR rate is defined as the proportion of participants who achieve a CHR during or after study treatment initiation, as assessed by the investigator, according to the consensus guidelines for AL amyloidosis.

Up to approximately 24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Número de participantes con eventos adversos no graves y eventos adversos graves
Periodo de tiempo: Hasta aproximadamente 24 meses
Hasta aproximadamente 24 meses
Número de participantes con cambios clínicamente significativos en los parámetros de hematología y química
Periodo de tiempo: Hasta aproximadamente 24 meses
Hasta aproximadamente 24 meses
Número de participantes con hallazgos oculares en el examen oftalmológico
Periodo de tiempo: Hasta aproximadamente 24 meses
Hasta aproximadamente 24 meses
Concentración plasmática máxima (Cmax) de belantamab mafodotin
Periodo de tiempo: Hasta 24 meses
Hasta 24 meses
Área bajo la curva de concentración-tiempo (AUC) de belantamab mafodotin
Periodo de tiempo: Hasta 24 meses
Hasta 24 meses
Cmax de Cisteína maleimidocapril monometil auristatina F (cys-mcMMAF)
Periodo de tiempo: Hasta 24 meses
Hasta 24 meses
AUC del cys-mcMMAF
Periodo de tiempo: Hasta 24 meses
Hasta 24 meses
Número de participantes con anticuerpos anti-fármaco (ADA) positivos contra belantamab mafodotin
Periodo de tiempo: Hasta aproximadamente 24 meses
Hasta aproximadamente 24 meses
Títulos de ADAs contra belantamab mafodotin
Periodo de tiempo: Hasta aproximadamente 24 meses
Hasta aproximadamente 24 meses
Organ response rate (OrRR)
Periodo de tiempo: Up to approximately 5 years

OrRR is defined as the proportions of participants who achieve confirmed organ response (cardiac, renal, or liver) in each organ as per consensus guidelines.

Up to approximately 5 years
Duration of CHR
Periodo de tiempo: Up to approximately 5 years

Duration of CHR is defined for participants with CHR as the time from the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive disease.

Up to approximately 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

24 de junio de 2026

Finalización primaria (Estimado)

12 de enero de 2033

Finalización del estudio (Estimado)

12 de enero de 2033

Fechas de registro del estudio

Enviado por primera vez

31 de octubre de 2025

Primero enviado que cumplió con los criterios de control de calidad

31 de octubre de 2025

Publicado por primera vez (Actual)

5 de noviembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir